Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE: 532523, NSE: BIOCON), has received approval from the U.S. Food and Drug Administration (FDA) for its bevacizumab biosimilar, Jobevne™ (bevacizumab-nwgd), for intravenous use.
Jobevne™ is a biosimilar to Avastin® (bevacizumab), a recombinant humanized monoclonal antibody. It acts as a vascular endothelial growth factor (VEGF) inhibitor by binding to VEGF and blocking its interaction with receptors, thereby helping to prevent angiogenesis—the formation of new blood vessels—which is a key factor in the growth of certain cancers.
This FDA approval marks the seventh biosimilar from Biocon Biologics to be approved in the United States. Jobevne™ adds to the company’s oncology-focused biosimilar portfolio in the U.S., which also includes:
-
OGIVRI (trastuzumab-dkst), a biosimilar to Herceptin®
-
FULPHILA (pegfilgrastim-jmdb), a biosimilar to Neulasta®
Biocon Biologics already markets bevacizumab in Europe and Canada under the brand name Abevmy, following approvals in February 2021 and November 2021, respectively.
According to industry estimates, U.S. sales of bevacizumab reached approximately $2.0 billion in 2023. Jobevne™’s entry into the U.S. market is expected to contribute to increasing access to biosimilar treatments in oncology care.
Biocon Biologics’ biosimilar pipeline includes 20 products across various therapeutic areas, including insulin and monoclonal antibodies. The company currently serves over 5 million patients annually and holds approvals for seven biosimilars in the U.S. and six in Canada.
